IP Library Granted Patent US 10,507,269
Granted Patent B2
US 10,507,269 · App. 16/373,850 · Granted Dec 17, 2019

Catheter lock solution formulations

Inventors: Lecon Woo (Libertyville, IL); William Anderson (Cary, IL)
Assignee: Medline Industries, Inc.
A61L33/04A61L29/14A61L29/16A61L33/0005A61L2300/404A61L2300/406A61L2300/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,507,269
App. No.
16/373,850
Granted
Dec 17, 2019
Kind
B2
Abstract

A liquid excipient is added to a lock solution formulation containing a lower alcohol and an anti-coagulant, antibiotic, and/or anti-microbial, such as the ethanol and tri-sodium citrate lock solution formulation, to prevent citrate from crystallizing in catheters made from silicone. The locking solution could include a liquid excipient, such as glycerol, polysorbate-20, or polyethylene glycol (PEG)-400, along with a lower alcohol, such as ethanol, and an anti-coagulant, such as tri-sodium citrate, antibiotic, and/or anti-microbial.

Claims (24)

1. A catheter locking method comprising: introducing a locking composition into a lumen of the implantable catheter, wherein the locking composition comprises:

ethanol;

an anti-coagulant comprising sodium citrate; and

an excipient that is liquid at room temperature, wherein the excipient comprises one or more of glycerol, polysorbate-20, polysorbate-80, polyethylene glycol-100, polyethylene glycol-200, polyethylene glycol-300, polyethylene glycol-400, poloxomer 124, macrogol 15 hydroxy stearate, polyoxyl 35 castor oil, and t-octylphenoxypolyethoxyethanol, the amount of the excipient being less than the amount of the anti-coagulant and being sufficient to inhibit crystallization of the sodium citrate.

2. The method of claim 1 , the locking composition comprising at least about 4% sodium citrate.

3. The method of claim 1 , further comprising an anti-microbial compound.

4. The method of claim 3 , the antimicrobial compound anti-microbial including one or more of taurolidine, triclosan, chlorhexidine, gentamicin, vancomycin, and combinations thereof.

5. The method of claim 4 , the locking composition comprising at least about 4% sodium citrate.

6. The method of claim 1 , the excipient being present in an amount ranging from about 0.5%-2% by weight of the locking composition.

7. The method of claim 1 , the excipient comprising one or more of glycerol, a polysorbate, a glycol, and a poloxomer.

8. The method of claim 1 , the anti-coagulant further comprising one or more of riboflavin, ethylene diamine tetraacetic acid, a heparin, and citric acid.

9. The method of claim 1 , the locking composition further comprising one or more lower alcohols other than ethanol.

10. A catheter locking method comprising: introducing a locking composition into a lumen of the implantable catheter, wherein the locking composition comprises:

a lower alcohol;

an anti-coagulant comprising sodium citrate; and

an excipient that is liquid at room temperature, wherein the excipient comprises one or more of glycerol, polysorbate-20, polysorbate-80, polyethylene glycol-100, polyethylene glycol-200, polyethylene glycol-300, polyethylene glycol-400, poloxomer 124, macrogol 15 hydroxy stearate, polyoxyl 35 castor oil, and t-octylphenoxypolyethoxyethanol, the amount of the excipient being sufficient to inhibit crystallization of the sodium citrate.

11. The method of claim 10 , the locking composition comprising at least about 4% sodium citrate.

12. The method of claim 10 , further comprising an anti-microbial.

13. The method of claim 12 , the anti-microbial including one or more of taurolidine, triclosan, chlorhexidine, gentamicin, vancomycin, and combinations thereof.

14. The method of claim 13 the locking composition comprising at least about 4% sodium citrate.

15. The method of claim 10 , the excipient being present in an amount ranging from about 0.5%-2% by weight of the locking composition.

16. The method of claim 10 , the excipient comprising at least one of glycerol, a polysorbate, a glycol, and a poloxomer.

17. The method of claim 10 , the anti-coagulant further comprising one or more of riboflavin, ethylene diamine tetraacetic acid, a heparin, and citric acid.

18. The method of claim 10 , the lower alcohol comprising one or more of ethanol, propanol, isopropanol, and butanol.

Assignments (5)
PATENT SECURITY AGREEMENT Recorded May 28, 2026
From: MEDLINE INDUSTRIES, LP
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT
Reel/Frame 075643/0462 →
PATENT SECURITY AGREEMENT Recorded Jun 20, 2025
From: MEDLINE INDUSTRIES, LP
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT
Reel/Frame 071672/0100 →
SECURITY INTEREST Recorded Oct 21, 2021
From: MEDLINE INDUSTRIES, LP
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057927/0091 →
SECURITY INTEREST Recorded Oct 21, 2021
From: MEDLINE INDUSTRIES, LP
To: BANK OF AMERICA, N.A.
Reel/Frame 058040/0001 →
CHANGE OF NAME Recorded Oct 20, 2021
From: MEDLINE INDUSTRIES, INC.
To: MEDLINE INDUSTRIES, LP
Reel/Frame 057876/0748 →